Clinical study of 77 participants comparing serum MOTS-c levels between obstructive sleep apnea patients and controls, finding significantly reduced MOTS-c in OSA patients correlated with disease severity markers and metabolic dysfunction. Identifies MOTS-c deficiency as a feature of OSA pathophysiology. Establishes reduced circulating MOTS-c as a biomarker of OSA severity—suggesting that intermittent hypoxia-driven mitochondrial dysfunction depletes MOTS-c and potentially linking MOTS-c deficiency to the metabolic complications (insulin resistance, cardiovascular risk) that characterize severe OSA.
Luo, Zhuoding; Ji, Rui; Ye, Renjing; Shi, Yawen; Pang, Qingfeng; Yin, Min